{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:22:19Z","timestamp":1792513339473,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1124\/jpet.119.258251","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T22:30:09Z","timestamp":1561415409000},"page":"459-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3\u2013Related Skeletal Dysplasias"],"prefix":"10.1016","volume":"370","author":[{"given":"Vibeke Miller","family":"Breinholt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Holse","family":"Mygind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Kjelgaard-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Faltinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Zettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Hersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.258251_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/en.2002-220702","article-title":"Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B","volume":"144","author":"Abbey","year":"2003","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.258251_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0196-9781(96)00110-6","article-title":"C-type natriuretic peptide","volume":"17","author":"Barr","year":"1996","journal-title":"Peptides"},{"key":"10.1124\/jpet.119.258251_bib3","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/j.1476-5381.1996.tb15605.x","article-title":"Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs","volume":"118","author":"Beaulieu","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.258251_bib4","first-page":"H1933","article-title":"Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs","volume":"273","author":"Beaulieu","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.119.258251_bib5","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1073\/pnas.0336365100","article-title":"Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor","volume":"100","author":"Chauhan","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.119.258251_bib6","first-page":"R290","article-title":"C-type natriuretic peptide: a selective cardiovascular peptide","volume":"264","author":"Clavell","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.119.258251_bib7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0006-291X(05)80284-0","article-title":"Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells","volume":"183","author":"Furuya","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.119.258251_bib8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.peptides.2004.08.035","article-title":"A new paradigm for hormone recognition and allosteric receptor activation revealed from structural studies of NPR-C","volume":"26","author":"He","year":"2005","journal-title":"Peptides"},{"key":"10.1124\/jpet.119.258251_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1291\/hypres.21.7","article-title":"Effects of intravenously administered C-type natriuretic peptide in humans: comparison with atrial natriuretic peptide","volume":"21","author":"Igaki","year":"1998","journal-title":"Hypertens Res"},{"key":"10.1124\/jpet.119.258251_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MOP.0b013e32833b7a69","article-title":"Achondroplasia: pathogenesis and implications for future treatment","volume":"22","author":"Laederich","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"10.1124\/jpet.119.258251_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000439334","article-title":"C-type natriuretic peptide analog as therapy for achondroplasia","volume":"30","author":"Legeai-Mallet","year":"2016","journal-title":"Endocr Dev"},{"key":"10.1124\/jpet.119.258251_bib12","doi-asserted-by":"crossref","first-page":"23064","DOI":"10.1074\/jbc.272.37.23064","article-title":"The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling","volume":"272","author":"Lopez","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.258251_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.119.258251_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.116.08219","article-title":"Endothelium-derived C-type natriuretic peptide contributes to blood pressure regulation by maintaining endothelial integrity","volume":"69","author":"Nakao","year":"2017","journal-title":"Hypertension"},{"key":"10.1124\/jpet.119.258251_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/jmbi.1999.3492","article-title":"Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon","volume":"296","author":"Oefner","year":"2000","journal-title":"J Mol Biol"},{"key":"10.1124\/jpet.119.258251_bib16","unstructured":"Rau H, Hersel U, Sprog\u00f8e K, Faltinger F, Wegge T, and Cleemann F (2017), inventors, Ascendis Pharma Growth Disorders A\/S, assignee. Controlled-release CNP agonists with low NPR-C binding. International Patent Application WO 2017\/118704. 2017 Jul 13"},{"key":"10.1124\/jpet.119.258251_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pharmthera.2004.08.011","article-title":"C-type natriuretic peptide in vascular physiology and disease","volume":"105","author":"Scotland","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.119.258251_bib18","unstructured":"Sprog\u00f8e K, Hersel U, Rau H, Wegge T, Faltinger F, Cleemann F, Kaluza N, Bernhard A, Buba A, and Woods T (2016) inventors, Ascendis Pharma Growth Disorders A\/S, assignee. CNP Prodrugs. International Patent Application WO 2016\/110577. 2016 Jul 14"},{"key":"10.1124\/jpet.119.258251_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/bmme.1997.2584","article-title":"Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11","volume":"61","author":"Watanabe","year":"1997","journal-title":"Biochem Mol Med"},{"key":"10.1124\/jpet.119.258251_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1124\/jpet.114.218560","article-title":"Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism","volume":"353","author":"Wendt","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.258251_bib21","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/en.2008-1676","article-title":"Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias","volume":"150","author":"Yasoda","year":"2009","journal-title":"Endocrinology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.258251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:54:27Z","timestamp":1739994867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524260717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0022356524260717"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.258251","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3\u2013Related Skeletal Dysplasias","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.258251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}